{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T04:21:18Z","timestamp":1793334078917,"version":"4.5.0"},"reference-count":192,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273460"],"award-info":[{"award-number":["82273460"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32260167"],"award-info":[{"award-number":["32260167"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Yunnan Applied Basic Research Projects","award":["202401AS070133"],"award-info":[{"award-number":["202401AS070133"]}]},{"name":"Yunnan Applied Basic Research Projects","award":["XDYC-YLWS-2023-0056"],"award-info":[{"award-number":["XDYC-YLWS-2023-0056"]}]},{"name":"Yunnan Applied Basic Research Projects","award":["YDYXJJ2025-0007"],"award-info":[{"award-number":["YDYXJJ2025-0007"]}]},{"DOI":"10.13039\/501100005147","name":"Applied Basic Research Key Project of Yunnan","doi-asserted-by":"publisher","award":["2024YNLCYXZX0084"],"award-info":[{"award-number":["2024YNLCYXZX0084"]}],"id":[{"id":"10.13039\/501100005147","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Open Research Program of NHC Key Laboratory of Healthy Birth and Birth Defect Prevention in Western China First People's Hospital of Yunnan Province","award":["2024XBYSKF003"],"award-info":[{"award-number":["2024XBYSKF003"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biomed"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cancer therapy has advanced substantially through targeted therapies and immunotherapy; however, durable clinical responses remain limited by the development of drug resistance. Increasing evidence identifies cancer stem cells (CSCs) as central drivers of therapeutic failure, tumor recurrence, metastasis, and minimal residual disease. CSCs possess self-renewal and differentiation capacities together with remarkable adaptability under therapeutic stress, enabling long-term tumor maintenance and regeneration. CSC-mediated resistance arises through coordinated intrinsic and extrinsic mechanisms. Intrinsically, CSCs employ multiple survival programs, including cellular quiescence, enhanced DNA damage response and repair, ATP-binding cassette transporter-mediated drug efflux, apoptosis evasion, and metabolic reprogramming. Extrinsically, these mechanisms are reinforced through dynamic interactions with the tumor microenvironment (TME), particularly hypoxic and perivascular niches that support stemness and therapeutic tolerance. Importantly, CSCs are increasingly recognized as dynamic cellular states rather than fixed populations and exhibit marked plasticity through reversible transitions between stem-like and non-stem states, frequently mediated by epithelial\u2013mesenchymal transition (EMT). This plasticity promotes intratumoral heterogeneity and replenishes resistant cell populations. In this review, we provide a comprehensive synthesis of the molecular and microenvironmental mechanisms underlying CSC-driven drug resistance and critically discuss emerging therapeutic strategies targeting CSC plasticity, niche interactions, metabolic adaptation, and immune evasion. Collectively, these insights support the development of integrated multi-target therapeutic approaches to improve long-term clinical outcomes.<\/jats:p>","DOI":"10.1186\/s43556-026-00516-2","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T07:17:16Z","timestamp":1784272636000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cancer stem cells and drug resistance in cancer: molecular mechanisms and therapeutic targets"],"prefix":"10.1186","volume":"7","author":[{"given":"Hayam","family":"Hamdy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youzhou","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoxuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ensong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doaa","family":"Safwat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junling","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3045-2724","authenticated-orcid":false,"given":"Jianwei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"key":"516_CR1","doi-asserted-by":"publisher","unstructured":"Erin N, Grahovac J, Brozovic A, Efferth T. Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance. Drug Resist Updat. 2020;53:100715. https:\/\/doi.org\/10.1016\/j.drup.2020.100715.","DOI":"10.1016\/j.drup.2020.100715"},{"issue":"1","key":"516_CR2","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12964-020-00627-5","volume":"19","author":"Y Li","year":"2021","unstructured":"Li Y, Wang Z, Ajani JA, Song S. Drug resistance and Cancer stem cells. Cell Commun Signal. 2021;19(1):19. https:\/\/doi.org\/10.1186\/s12964-020-00627-5.","journal-title":"Cell Commun Signal"},{"issue":"10","key":"516_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.710","volume":"5","author":"TC Dakal","year":"2020","unstructured":"Dakal TC, Bhushan R, Xu C, Gadi BR, Cameotra SS, Yadav V, et al. Intricate relationship between cancer stemness, metastasis, and drug resistance. MedComm. 2020;5(10):e710. https:\/\/doi.org\/10.1002\/mco2.710.","journal-title":"MedComm"},{"key":"516_CR4","doi-asserted-by":"publisher","unstructured":"Roszkowska M. Multilevel Mechanisms of Cancer Drug Resistance. Int J Mol Sci. 2024;25(22). https:\/\/doi.org\/10.3390\/ijms252212402.","DOI":"10.3390\/ijms252212402"},{"issue":"8","key":"516_CR5","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.3390\/cells9081896","volume":"9","author":"K Dzobo","year":"2020","unstructured":"Dzobo K, Senthebane DA, Ganz C, Thomford NE, Wonkam A, Dandara C. Advances in Therapeutic Targeting of Cancer Stem Cells within the Tumor Microenvironment: An Updated Review. Cells. 2020;9(8):1896. https:\/\/doi.org\/10.3390\/cells9081896.","journal-title":"Cells"},{"key":"516_CR6","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2025.5831","author":"H Xu","year":"2026","unstructured":"Xu H, Si Q, Song Y, Sun S, Wei X, Long H, et al. Cancer stem cell heterogeneity\u2011inspired therapeutics for enhancing tumor treatment outcomes (review). Int J Oncol. 2026. https:\/\/doi.org\/10.3892\/ijo.2025.5831.","journal-title":"Int J Oncol"},{"key":"516_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.105020","volume":"217","author":"MDA Tarmizi","year":"2026","unstructured":"Tarmizi MDA, Ramasamy TS. The evolving role of alternative splicing in cancer stem cell plasticity: From mechanisms to clinical opportunities. Crit Rev Oncol Hematol. 2026;217:105020. https:\/\/doi.org\/10.1016\/j.critrevonc.2025.105020.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"516_CR8","doi-asserted-by":"publisher","first-page":"850","DOI":"10.20517\/cdr.2022.20","volume":"5","author":"AR Safa","year":"2022","unstructured":"Safa AR. Drug and apoptosis resistance in cancer stem cells: a puzzle with many pieces. Cancer Drug Resist. 2022;5(4):850\u201372. https:\/\/doi.org\/10.20517\/cdr.2022.20.","journal-title":"Cancer Drug Resist"},{"key":"516_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.702642","volume":"11","author":"M Gaggianesi","year":"2021","unstructured":"Gaggianesi M, Di Franco S, Pantina VD, Porcelli G, D\u2019Accardo C, Verona F, et al. Messing Up the Cancer Stem Cell Chemoresistance Mechanisms Supported by Tumor Microenvironment. Front Oncol. 2021;11:702642. https:\/\/doi.org\/10.3389\/fonc.2021.702642.","journal-title":"Front Oncol"},{"key":"516_CR10","doi-asserted-by":"publisher","first-page":"684","DOI":"10.20517\/cdr.2021.32","volume":"4","author":"H Zhang","year":"2021","unstructured":"Zhang H, Steed A, Co M, Chen X. Cancer stem cells, epithelial-mesenchymal transition, ATP and their roles in drug resistance in cancer. Cancer Drug Resist. 2021;4:684\u2013709. https:\/\/doi.org\/10.20517\/cdr.2021.32.","journal-title":"Cancer Drug Resist"},{"issue":"2","key":"516_CR11","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.trecan.2023.09.013","volume":"10","author":"L Duvivier","year":"2024","unstructured":"Duvivier L, Gerard L, Diaz A, Gillet JP. Linking ABC transporters to the hallmarks of cancer. Trends Cancer. 2024;10(2):124\u201334. https:\/\/doi.org\/10.1016\/j.trecan.2023.09.013.","journal-title":"Trends Cancer"},{"issue":"2","key":"516_CR12","doi-asserted-by":"publisher","first-page":"253","DOI":"10.20892\/j.issn.2095-3941.2019.0284","volume":"17","author":"W Muriithi","year":"2020","unstructured":"Muriithi W, Macharia LW, Heming CP, Echevarria JL, Nyachieo A, Filho PN, et al. ABC transporters and the hallmarks of cancer: roles in cancer aggressiveness beyond multidrug resistance. Cancer Biol Med. 2020;17(2):253\u201369. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2019.0284.","journal-title":"Cancer Biol Med"},{"key":"516_CR13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s42764-019-00003-9","volume":"1","author":"D Menolfi","year":"2019","unstructured":"Menolfi D, Zha S. ATM, DNA-PKcs and ATR: shaping development through the regulation of the DNA damage responses. Genome Instability & Disease. 2019;1:47\u201368.","journal-title":"Genome Instability & Disease"},{"issue":"1","key":"516_CR14","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s13073-025-01509-6","volume":"17","author":"RM Chabanon","year":"2025","unstructured":"Chabanon RM, Danlos FX, Ouali K, Postel-Vinay S. Genome instability and crosstalk with the immune response. Genome Med. 2025;17(1):139. https:\/\/doi.org\/10.1186\/s13073-025-01509-6.","journal-title":"Genome Med"},{"issue":"1","key":"516_CR15","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12964-022-00888-2","volume":"20","author":"X Chen","year":"2022","unstructured":"Chen X, Yang M, Yin J, Li P, Zeng S, Zheng G, et al. Tumor-associated macrophages promote epithelial-mesenchymal transition and the cancer stem cell properties in triple-negative breast cancer through CCL2\/AKT\/\u03b2-catenin signaling. Cell Commun Signal. 2022;20(1):92. https:\/\/doi.org\/10.1186\/s12964-022-00888-2.","journal-title":"Cell Commun Signal"},{"key":"516_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2019.116781","volume":"234","author":"M Najafi","year":"2019","unstructured":"Najafi M, Mortezaee K, Majidpoor J. Cancer stem cell (CSC) resistance drivers. Life Sci. 2019;234:116781. https:\/\/doi.org\/10.1016\/j.lfs.2019.116781.","journal-title":"Life Sci"},{"issue":"12","key":"516_CR17","doi-asserted-by":"publisher","first-page":"985","DOI":"10.20892\/j.issn.2095-3941.2023.0333","volume":"20","author":"S Zhang","year":"2024","unstructured":"Zhang S, Yang R, Ouyang Y, Shen Y, Hu L, Xu C. Cancer stem cells: a target for overcoming therapeutic resistance and relapse. Cancer Biol Med. 2024;20(12):985\u20131020. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2023.0333.","journal-title":"Cancer Biol Med"},{"issue":"8","key":"516_CR18","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.stem.2024.06.003","volume":"31","author":"PE Saw","year":"2024","unstructured":"Saw PE, Liu Q, Wong P-P, Song E. Cancer stem cell mimicry for immune evasion and therapeutic resistance. Cell Stem Cell. 2024;31(8):1101\u201312. https:\/\/doi.org\/10.1016\/j.stem.2024.06.003.","journal-title":"Cell Stem Cell"},{"key":"516_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.70406","author":"H Wang","year":"2025","unstructured":"Wang H, Li J, Du F, Deng H. Cancer stem cells: bridging microenvironmental interactions and clinical therapy. Clin Transl Med. 2025. https:\/\/doi.org\/10.1002\/ctm2.70406.","journal-title":"Clin Transl Med"},{"key":"516_CR20","doi-asserted-by":"publisher","first-page":"1619597","DOI":"10.3389\/fcell.2025.1619597","volume":"13","author":"L Yin","year":"2025","unstructured":"Yin L, Zhou S, Zhang H, Shang Y, Wu S, Jin T. Cancer stem cells in personalized therapy: mechanisms, microenvironment crosstalk, and therapeutic vulnerabilities. Front Cell Dev Biol. 2025;13:1619597. https:\/\/doi.org\/10.3389\/fcell.2025.1619597.","journal-title":"Front Cell Dev Biol"},{"key":"516_CR21","doi-asserted-by":"publisher","unstructured":"Lee H, Kim B, Park J, Park S, Yoo G, Yum S, et al. Cancer stem cells: landscape, challenges and emerging therapeutic innovations. Signal Transduct Target Therapy. 2025;10(1). https:\/\/doi.org\/10.1038\/s41392-025-02360-2.","DOI":"10.1038\/s41392-025-02360-2"},{"key":"516_CR22","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/5416923","author":"LTH Phi","year":"2018","unstructured":"Phi LTH, Sari IN, Yang YG, Lee SH, Jun N, Kim KS, et al. Cancer stem cells (CSCs) in drug resistance and their therapeutic implications in cancer treatment. Stem Cells Int. 2018. https:\/\/doi.org\/10.1155\/2018\/5416923.","journal-title":"Stem Cells Int"},{"issue":"1","key":"516_CR23","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s13287-022-02856-6","volume":"13","author":"H Rezayatmand","year":"2022","unstructured":"Rezayatmand H, Razmkhah M, Razeghian-Jahromi I. Drug resistance in cancer therapy: the Pandora\u2019s Box of cancer stem cells. Stem Cell Res Ther. 2022;13(1):181. https:\/\/doi.org\/10.1186\/s13287-022-02856-6.","journal-title":"Stem Cell Res Ther"},{"issue":"6","key":"516_CR24","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.2741\/e531","volume":"4","author":"B Malik","year":"2012","unstructured":"Malik B, Nie D. Cancer stem cells and resistance to chemo and radio therapy. Front Biosci (Elite Ed). 2012;4(6):2142\u20139. https:\/\/doi.org\/10.2741\/e531.","journal-title":"Front Biosci (Elite Ed)"},{"issue":"5","key":"516_CR25","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.stem.2024.04.004","volume":"31","author":"JJ Loh","year":"2024","unstructured":"Loh JJ, Ma S. Hallmarks of cancer stemness. Cell Stem Cell. 2024;31(5):617\u201339. https:\/\/doi.org\/10.1016\/j.stem.2024.04.004.","journal-title":"Cell Stem Cell"},{"key":"516_CR26","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/941876","volume":"2011","author":"R Morrison","year":"2011","unstructured":"Morrison R, Schleicher SM, Sun Y, Niermann KJ, Kim S, Spratt DE, et al. Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell hypothesis. J Oncol. 2011;2011:941876. https:\/\/doi.org\/10.1155\/2011\/941876.","journal-title":"J Oncol"},{"key":"516_CR27","doi-asserted-by":"publisher","first-page":"764","DOI":"10.3389\/fonc.2020.00764","volume":"10","author":"Y Cho","year":"2020","unstructured":"Cho Y, Kim YK. Cancer Stem Cells as a Potential Target to Overcome Multidrug Resistance. Front Oncol. 2020;10:764. https:\/\/doi.org\/10.3389\/fonc.2020.00764.","journal-title":"Front Oncol"},{"issue":"2","key":"516_CR28","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1080\/1354750x.2022.2157875","volume":"28","author":"S Hoque","year":"2023","unstructured":"Hoque S, Dhar R, Kar R, Mukherjee S, Mukherjee D, Mukerjee N, et al. Cancer stem cells (CSCs): key player of radiotherapy resistance and its clinical significance. Biomarkers. 2023;28(2):139\u201351. https:\/\/doi.org\/10.1080\/1354750x.2022.2157875.","journal-title":"Biomarkers"},{"key":"516_CR29","first-page":"77","volume-title":"Oncogenomics","author":"F Islam","year":"2019","unstructured":"Islam F, Gopalan V, Lam AK-Y. Chapter 6 - Cancer stem cells: role in tumor progression and treatment resistance. In: Dammacco F, Silvestris F, editors. Oncogenomics. Academic Press; 2019. p. 77\u201387."},{"key":"516_CR30","doi-asserted-by":"publisher","unstructured":"Li Y, Wang Z, Ajani JA, Song S. Drug resistance and Cancer stem cells. Cell Commun Signal. 2021;19(1). https:\/\/doi.org\/10.1186\/s12964-020-00627-5.","DOI":"10.1186\/s12964-020-00627-5"},{"issue":"1","key":"516_CR31","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s40199-024-00545-8","volume":"33","author":"R Shaik","year":"2024","unstructured":"Shaik R, Malik MS, Basavaraju S, Qurban J, Al-Subhi FMM, Badampudi S, et al. Cellular and molecular aspects of drug resistance in cancers. Daru. 2024;33(1):4. https:\/\/doi.org\/10.1007\/s40199-024-00545-8.","journal-title":"Daru"},{"key":"516_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12081801","author":"M Koirala","year":"2024","unstructured":"Koirala M, DiPaola M. Overcoming cancer resistance: strategies and modalities for effective treatment. Biomedicines. 2024. https:\/\/doi.org\/10.3390\/biomedicines12081801.","journal-title":"Biomedicines"},{"issue":"7","key":"516_CR33","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1007\/s12015-023-10593-3","volume":"19","author":"Q Gao","year":"2023","unstructured":"Gao Q, Zhan Y, Sun L, Zhu W. Cancer Stem Cells and the Tumor Microenvironment in Tumor Drug Resistance. Stem Cell Reviews and Reports. 2023;19(7):2141\u201354. https:\/\/doi.org\/10.1007\/s12015-023-10593-3.","journal-title":"Stem Cell Reviews and Reports"},{"issue":"9","key":"516_CR34","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","volume":"121","author":"A Leonetti","year":"2019","unstructured":"Leonetti A, Sharma S, Minari R, Perego P, Giovannetti E, Tiseo M. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br J Cancer. 2019;121(9):725\u201337. https:\/\/doi.org\/10.1038\/s41416-019-0573-8.","journal-title":"Br J Cancer"},{"key":"516_CR35","doi-asserted-by":"publisher","unstructured":"Marzagalli M, Fontana F, Raimondi M, Limonta P. Cancer Stem Cells-Key Players in Tumor Relapse. Cancers (Basel). 2021;13(3). https:\/\/doi.org\/10.3390\/cancers13030376.","DOI":"10.3390\/cancers13030376"},{"key":"516_CR36","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/1749-799x-5-78","volume":"5","author":"VA Siclari","year":"2010","unstructured":"Siclari VA, Qin L. Targeting the osteosarcoma cancer stem cell. J Orthop Surg Res. 2010;5:78. https:\/\/doi.org\/10.1186\/1749-799x-5-78.","journal-title":"J Orthop Surg Res"},{"key":"516_CR37","doi-asserted-by":"publisher","unstructured":"Cortes-Dericks L, Galetta D. Impact of Cancer Stem Cells and Cancer Stem Cell-Driven Drug Resiliency in Lung Tumor: Options in Sight. Cancers (Basel). 2022;14(2). https:\/\/doi.org\/10.3390\/cancers14020267.","DOI":"10.3390\/cancers14020267"},{"key":"516_CR38","doi-asserted-by":"publisher","unstructured":"Gillespie MS, Ward CM, Davies CC. DNA Repair and Therapeutic Strategies in Cancer Stem Cells. Cancers (Basel). 2023;15(6). https:\/\/doi.org\/10.3390\/cancers15061897.","DOI":"10.3390\/cancers15061897"},{"key":"516_CR39","doi-asserted-by":"publisher","unstructured":"Tu SM, Guo CC, Chow DS, Zacharias NM. Stem Cell Theory of Cancer: Implications for Drug Resistance and Chemosensitivity in Cancer Care. Cancers (Basel). 2022;14(6). https:\/\/doi.org\/10.3390\/cancers14061548.","DOI":"10.3390\/cancers14061548"},{"key":"516_CR40","doi-asserted-by":"publisher","unstructured":"Kazi JU. Mechanisms of Anticancer Therapy Resistance: The Role of Cancer Stem Cells. Int J Mol Sci. 2020;21(23). https:\/\/doi.org\/10.3390\/ijms21239006.","DOI":"10.3390\/ijms21239006"},{"issue":"6","key":"516_CR41","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.3390\/cancers15061897","volume":"15","author":"MS Gillespie","year":"2023","unstructured":"Gillespie MS, Ward CM, Davies CC. DNA Repair and Therapeutic Strategies in Cancer Stem Cells. Cancers. 2023;15(6):1897. https:\/\/doi.org\/10.3390\/cancers15061897.","journal-title":"Cancers"},{"issue":"10","key":"516_CR42","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1038\/s41422-021-00528-3","volume":"31","author":"XN Zhang","year":"2021","unstructured":"Zhang XN, Yang KD, Chen C, He ZC, Wang QH, Feng H, et al. Pericytes augment glioblastoma cell resistance to temozolomide through CCL5-CCR5 paracrine signaling. Cell Res. 2021;31(10):1072\u201387. https:\/\/doi.org\/10.1038\/s41422-021-00528-3.","journal-title":"Cell Res"},{"issue":"7","key":"516_CR43","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1007\/s12015-023-10593-3","volume":"19","author":"Q Gao","year":"2023","unstructured":"Gao Q, Zhan Y, Sun L, Zhu W. Cancer Stem Cells and the Tumor Microenvironment in Tumor Drug Resistance. Stem Cell Rev Rep. 2023;19(7):2141\u201354. https:\/\/doi.org\/10.1007\/s12015-023-10593-3.","journal-title":"Stem Cell Rev Rep"},{"issue":"1","key":"516_CR44","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13045-025-01684-4","volume":"18","author":"T Shang","year":"2025","unstructured":"Shang T, Jia Z, Li J, Cao H, Xu H, Cong L, et al. Unraveling the triad of hypoxia, cancer cell stemness, and drug resistance. J Hematol Oncol. 2025;18(1):32. https:\/\/doi.org\/10.1186\/s13045-025-01684-4.","journal-title":"J Hematol Oncol"},{"key":"516_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2024.101084","volume":"74","author":"H Zhao","year":"2024","unstructured":"Zhao H, Ling Y, He J, Dong J, Mo Q, Wang Y, et al. Potential targets and therapeutics for cancer stem cell-based therapy against drug resistance in hepatocellular carcinoma. Drug Resist Updat. 2024;74:101084. https:\/\/doi.org\/10.1016\/j.drup.2024.101084.","journal-title":"Drug Resist Updat"},{"key":"516_CR46","doi-asserted-by":"publisher","unstructured":"Begicevic RR, Falasca M. ABC Transporters in Cancer Stem Cells: Beyond Chemoresistance. Int J Mol Sci. 2017;18(11). https:\/\/doi.org\/10.3390\/ijms18112362.","DOI":"10.3390\/ijms18112362"},{"key":"516_CR47","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.semcancer.2019.08.006","volume":"60","author":"S Nobili","year":"2020","unstructured":"Nobili S, Lapucci A, Landini I, Coronnello M, Roviello G, Mini E. Role of ATP-binding cassette transporters in cancer initiation and progression. Semin Cancer Biol. 2020;60:72\u201395. https:\/\/doi.org\/10.1016\/j.semcancer.2019.08.006.","journal-title":"Semin Cancer Biol"},{"issue":"3","key":"516_CR48","doi-asserted-by":"publisher","first-page":"339","DOI":"10.15171\/apb.2017.041","volume":"7","author":"B Mansoori","year":"2017","unstructured":"Mansoori B, Mohammadi A, Davudian S, Shirjang S, Baradaran B. The Different Mechanisms of Cancer Drug Resistance: A Brief Review. Adv Pharm Bull. 2017;7(3):339\u201348. https:\/\/doi.org\/10.15171\/apb.2017.041.","journal-title":"Adv Pharm Bull"},{"key":"516_CR49","doi-asserted-by":"publisher","first-page":"1379822","DOI":"10.3389\/fmolb.2024.1379822","volume":"11","author":"B Ren","year":"2024","unstructured":"Ren B, Li X, Zhang Z, Tai S, Yu S. Exosomes: a significant medium for regulating drug resistance through cargo delivery. Front Mol Biosci. 2024;11:1379822. https:\/\/doi.org\/10.3389\/fmolb.2024.1379822.","journal-title":"Front Mol Biosci"},{"key":"516_CR50","doi-asserted-by":"publisher","unstructured":"Santos P, Almeida F. Role of Exosomal miRNAs and the Tumor Microenvironment in Drug Resistance. Cells. 2020;9(6). https:\/\/doi.org\/10.3390\/cells9061450.","DOI":"10.3390\/cells9061450"},{"key":"516_CR51","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.semcancer.2019.07.022","volume":"60","author":"Y Garcia-Mayea","year":"2020","unstructured":"Garcia-Mayea Y, Mir C, Masson F, Paciucci R, Lleonart ME. Insights into new mechanisms and models of cancer stem cell multidrug resistance. Semin Cancer Biol. 2020;60:166\u201380. https:\/\/doi.org\/10.1016\/j.semcancer.2019.07.022.","journal-title":"Semin Cancer Biol"},{"key":"516_CR52","doi-asserted-by":"publisher","unstructured":"Sun H-R, Wang S, Yan S-C, Zhang Y, Nelson PJ, Jia H-L, et al. Therapeutic Strategies Targeting Cancer Stem Cells and Their Microenvironment. Front Oncol. 2019;9. https:\/\/doi.org\/10.3389\/fonc.2019.01104.","DOI":"10.3389\/fonc.2019.01104"},{"key":"516_CR53","doi-asserted-by":"publisher","unstructured":"Carnero A, Lleonart M. The hypoxic microenvironment: A determinant of cancer stem cell evolution. BioEssays. 2016;38. https:\/\/doi.org\/10.1002\/bies.201670911.","DOI":"10.1002\/bies.201670911"},{"issue":"1","key":"516_CR54","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-022-02904-1","volume":"13","author":"F Ju","year":"2022","unstructured":"Ju F, Atyah MM, Horstmann N, Gul S, Vago R, Bruns CJ, et al. Characteristics of the cancer stem cell niche and therapeutic strategies. Stem Cell Res Ther. 2022;13(1):233. https:\/\/doi.org\/10.1186\/s13287-022-02904-1.","journal-title":"Stem Cell Res Ther"},{"key":"516_CR55","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.mam.2015.09.004","volume":"47-48","author":"GL Semenza","year":"2016","unstructured":"Semenza GL. Dynamic regulation of stem cell specification and maintenance by hypoxia-inducible factors. Mol Aspects Med. 2016;47\u201348:15\u201323. https:\/\/doi.org\/10.1016\/j.mam.2015.09.004.","journal-title":"Mol Aspects Med"},{"key":"516_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2019.116952","volume":"237","author":"F Hajizadeh","year":"2019","unstructured":"Hajizadeh F, Okoye I, Esmaily M, Ghasemi Chaleshtari M, Masjedi A, Azizi G, et al. Hypoxia inducible factors in the tumor microenvironment as therapeutic targets of cancer stem cells. Life Sci. 2019;237:116952. https:\/\/doi.org\/10.1016\/j.lfs.2019.116952.","journal-title":"Life Sci"},{"issue":"8","key":"516_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2025.167993","volume":"1871","author":"Q Zhang","year":"2025","unstructured":"Zhang Q, Han Z, Liu JH, Li M, Li W, Zhou X, et al. Hypoxia facilitates stemness of colon cancer cells via histone lactylation. Biochimica et Biophysica Acta (BBA). 2025;1871(8):167993. https:\/\/doi.org\/10.1016\/j.bbadis.2025.167993.","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"key":"516_CR58","doi-asserted-by":"publisher","unstructured":"Chen Z, Han F, Du Y, Shi H, Zhou W. Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. Signal Transduct Targeted Therapy. 2023;8(1). https:\/\/doi.org\/10.1038\/s41392-023-01332-8.","DOI":"10.1038\/s41392-023-01332-8"},{"issue":"6","key":"516_CR59","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1007\/s11033-018-4309-2","volume":"45","author":"P Koka","year":"2018","unstructured":"Koka P, Mundre RS, Rangarajan R, Chandramohan Y, Subramanian RK, Dhanasekaran A. Uncoupling Warburg effect and stemness in CD133(+ve) cancer stem cells from Saos-2 (osteosarcoma) cell line under hypoxia. Mol Biol Rep. 2018;45(6):1653\u201362. https:\/\/doi.org\/10.1007\/s11033-018-4309-2.","journal-title":"Mol Biol Rep"},{"issue":"1","key":"516_CR60","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00432-019-03080-1","volume":"146","author":"M Najafi","year":"2020","unstructured":"Najafi M, Farhood B, Mortezaee K, Kharazinejad E, Majidpoor J, Ahadi R. Hypoxia in solid tumors: a key promoter of cancer stem cell (CSC) resistance. J Cancer Res Clin Oncol. 2020;146(1):19\u201331. https:\/\/doi.org\/10.1007\/s00432-019-03080-1.","journal-title":"J Cancer Res Clin Oncol"},{"key":"516_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110623","volume":"130","author":"X Sun","year":"2020","unstructured":"Sun X, Lv X, Yan Y, Zhao Y, Ma R, He M, et al. Hypoxia-mediated cancer stem cell resistance and targeted therapy. Biomed Pharmacother. 2020;130:110623. https:\/\/doi.org\/10.1016\/j.biopha.2020.110623.","journal-title":"Biomed Pharmacother"},{"key":"516_CR62","doi-asserted-by":"publisher","first-page":"1222575","DOI":"10.3389\/fonc.2023.1222575","volume":"13","author":"RF Zaarour","year":"2023","unstructured":"Zaarour RF, Ribeiro M, Azzarone B, Kapoor S, Chouaib S. Tumor microenvironment-induced tumor cell plasticity: relationship with hypoxic stress and impact on tumor resistance. Front Oncol. 2023;13:1222575. https:\/\/doi.org\/10.3389\/fonc.2023.1222575.","journal-title":"Front Oncol"},{"key":"516_CR63","doi-asserted-by":"publisher","unstructured":"Pathak L, Pal B, Talukdar J, Saikia PJ, Sandhya S, Tasabehji W, et al. Hypoxia-driven mobilization of altruistic cancer stem cells in platinum-treated head and neck cancer. Front Immunol. 2025;15. https:\/\/doi.org\/10.3389\/fimmu.2024.1336882.","DOI":"10.3389\/fimmu.2024.1336882"},{"issue":"11","key":"516_CR64","doi-asserted-by":"publisher","first-page":"7527","DOI":"10.1007\/s11033-021-06809-9","volume":"48","author":"MA Rainho","year":"2021","unstructured":"Rainho MA, Mencalha AL, Thole AA. Hypoxia effects on cancer stem cell phenotype in colorectal cancer: a mini-review. Mol Biol Rep. 2021;48(11):7527\u201335. https:\/\/doi.org\/10.1007\/s11033-021-06809-9.","journal-title":"Mol Biol Rep"},{"issue":"9","key":"516_CR65","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1007\/s11626-021-00625-y","volume":"57","author":"AZ Ayob","year":"2021","unstructured":"Ayob AZ, Ramasamy TS. Prolonged hypoxia switched on cancer stem cell-like plasticity in HepG2 tumourspheres cultured in serum-free media. In Vitro Cell Dev Biol Anim. 2021;57(9):896\u2013911. https:\/\/doi.org\/10.1007\/s11626-021-00625-y.","journal-title":"In Vitro Cell Dev Biol Anim"},{"issue":"1","key":"516_CR66","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12935-020-01719-5","volume":"21","author":"A Emami Nejad","year":"2021","unstructured":"Emami Nejad A, Najafgholian S, Rostami A, Sistani A, Shojaeifar S, Esparvarinha M, et al. The role of hypoxia in the tumor microenvironment and development of cancer stem cell: a novel approach to developing treatment. Cancer Cell Int. 2021;21(1):62. https:\/\/doi.org\/10.1186\/s12935-020-01719-5.","journal-title":"Cancer Cell Int"},{"key":"516_CR67","doi-asserted-by":"publisher","unstructured":"Liu Q, Guo Z, Li G, Zhang Y, Liu X, Li B, et al. Cancer stem cells and their niche in cancer progression and therapy. Cancer Cell Int. 2023;23(1). https:\/\/doi.org\/10.1186\/s12935-023-03130-2.","DOI":"10.1186\/s12935-023-03130-2"},{"key":"516_CR68","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/978-3-030-12734-3_3","volume":"1136","author":"J Qian","year":"2019","unstructured":"Qian J, Rankin EB. Hypoxia-Induced Phenotypes that Mediate Tumor Heterogeneity. Adv Exp Med Biol. 2019;1136:43\u201355. https:\/\/doi.org\/10.1007\/978-3-030-12734-3_3.","journal-title":"Adv Exp Med Biol"},{"issue":"5","key":"516_CR69","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/sj.bjc.6605551","volume":"102","author":"JM Heddleston","year":"2010","unstructured":"Heddleston JM, Li Z, Lathia JD, Bao S, Hjelmeland AB, Rich JN. Hypoxia inducible factors in cancer stem cells. Br J Cancer. 2010;102(5):789\u201395. https:\/\/doi.org\/10.1038\/sj.bjc.6605551.","journal-title":"Br J Cancer"},{"issue":"11","key":"516_CR70","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.trecan.2023.06.010","volume":"9","author":"A Nowosad","year":"2023","unstructured":"Nowosad A, Marine JC, Karras P. Perivascular niches: critical hubs in cancer evolution. Trends Cancer. 2023;9(11):897\u2013910. https:\/\/doi.org\/10.1016\/j.trecan.2023.06.010.","journal-title":"Trends Cancer"},{"issue":"3","key":"516_CR71","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.bbrc.2015.12.022","volume":"473","author":"A Sharma","year":"2016","unstructured":"Sharma A, Shiras A. Cancer stem cell-vascular endothelial cell interactions in glioblastoma. Biochem Biophys Res Commun. 2016;473(3):688\u201392. https:\/\/doi.org\/10.1016\/j.bbrc.2015.12.022.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"516_CR72","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/cco.0000000000000417","volume":"30","author":"G Seano","year":"2018","unstructured":"Seano G. Targeting the perivascular niche in brain tumors. Curr Opin Oncol. 2018;30(1):54\u201360. https:\/\/doi.org\/10.1097\/cco.0000000000000417.","journal-title":"Curr Opin Oncol"},{"issue":"15","key":"516_CR73","doi-asserted-by":"publisher","first-page":"3012","DOI":"10.4161\/cc.9.15.12710","volume":"9","author":"N Charles","year":"2010","unstructured":"Charles N, Holland EC. The perivascular niche microenvironment in brain tumor progression. Cell Cycle. 2010;9(15):3012\u201321. https:\/\/doi.org\/10.4161\/cc.9.15.12710.","journal-title":"Cell Cycle"},{"issue":"6","key":"516_CR74","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.stemcr.2024.04.009","volume":"19","author":"Q Chen","year":"2024","unstructured":"Chen Q, Hirai H, Chan M, Zhang J, Cho M, Randell SH, et al. Characterization of perivascular alveolar epithelial stem cells and their niche in lung homeostasis and cancer. Stem Cell Reports. 2024;19(6):890\u2013905. https:\/\/doi.org\/10.1016\/j.stemcr.2024.04.009.","journal-title":"Stem Cell Reports"},{"issue":"3","key":"516_CR75","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1002\/path.4904","volume":"242","author":"F Winkler","year":"2017","unstructured":"Winkler F. Hostile takeover: how tumours hijack pre-existing vascular environments to thrive. J Pathol. 2017;242(3):267\u201372. https:\/\/doi.org\/10.1002\/path.4904.","journal-title":"J Pathol"},{"issue":"4","key":"516_CR76","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s13402-021-00602-3","volume":"44","author":"J Majidpoor","year":"2021","unstructured":"Majidpoor J, Mortezaee K. Angiogenesis as a hallmark of solid tumors - clinical perspectives. Cell Oncol. 2021;44(4):715\u201337. https:\/\/doi.org\/10.1007\/s13402-021-00602-3.","journal-title":"Cell Oncol"},{"issue":"1","key":"516_CR77","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.stem.2018.12.009","volume":"24","author":"BC Prager","year":"2019","unstructured":"Prager BC, Xie Q, Bao S, Rich JN. Cancer stem cells: the architects of the tumor ecosystem. Cell Stem Cell. 2019;24(1):41\u201353. https:\/\/doi.org\/10.1016\/j.stem.2018.12.009.","journal-title":"Cell Stem Cell"},{"issue":"1","key":"516_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.108597","volume":"34","author":"P Chen","year":"2021","unstructured":"Chen P, Hsu W-H, Han J, Xia Y, DePinho RA. Cancer stemness meets immunity: from mechanism to therapy. Cell Rep. 2021;34(1):108597. https:\/\/doi.org\/10.1016\/j.celrep.2020.108597.","journal-title":"Cell Rep"},{"issue":"1","key":"516_CR79","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/imr.12984","volume":"302","author":"J Sbierski-Kind","year":"2021","unstructured":"Sbierski-Kind J, Mroz N, Molofsky AB. Perivascular stromal cells: Directors of tissue immune niches. Immunol Rev. 2021;302(1):10\u201331. https:\/\/doi.org\/10.1111\/imr.12984.","journal-title":"Immunol Rev"},{"key":"516_CR80","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.coi.2020.03.009","volume":"64","author":"A Benabid","year":"2020","unstructured":"Benabid A, Peduto L. Mesenchymal perivascular cells in immunity and disease. Curr Opin Immunol. 2020;64:50\u20135. https:\/\/doi.org\/10.1016\/j.coi.2020.03.009.","journal-title":"Curr Opin Immunol"},{"issue":"1","key":"516_CR81","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-017-0595-x","volume":"16","author":"C Melzer","year":"2017","unstructured":"Melzer C, von der Ohe J, Lehnert H, Ungefroren H, Hass R. Cancer stem cell niche models and contribution by mesenchymal stroma\/stem cells. Mol Cancer. 2017;16(1):28. https:\/\/doi.org\/10.1186\/s12943-017-0595-x.","journal-title":"Mol Cancer"},{"issue":"1","key":"516_CR82","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.apsb.2020.09.016","volume":"11","author":"H Duan","year":"2021","unstructured":"Duan H, Liu Y, Gao Z, Huang W. Recent advances in drug delivery systems for targeting cancer stem cells. Acta Pharm Sin B. 2021;11(1):55\u201370. https:\/\/doi.org\/10.1016\/j.apsb.2020.09.016.","journal-title":"Acta Pharm Sin B"},{"issue":"23","key":"516_CR83","doi-asserted-by":"publisher","first-page":"4287","DOI":"10.1007\/s00018-017-2646-2","volume":"74","author":"D Cui","year":"2017","unstructured":"Cui D, Huang Z, Liu Y, Ouyang G. The multifaceted role of periostin in priming the tumor microenvironments for tumor progression. Cell Mol Life Sci. 2017;74(23):4287\u201391. https:\/\/doi.org\/10.1007\/s00018-017-2646-2.","journal-title":"Cell Mol Life Sci"},{"key":"516_CR84","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/978-981-13-6657-4_13","volume":"1132","author":"Y Liu","year":"2019","unstructured":"Liu Y, Huang Z, Cui D, Ouyang G. The Multiaspect Functions of Periostin in Tumor Progression. Adv Exp Med Biol. 2019;1132:125\u201336. https:\/\/doi.org\/10.1007\/978-981-13-6657-4_13.","journal-title":"Adv Exp Med Biol"},{"key":"516_CR85","doi-asserted-by":"publisher","first-page":"1655019","DOI":"10.3389\/fimmu.2025.1655019","volume":"16","author":"M Maddalena","year":"2025","unstructured":"Maddalena M, Dimitrov J, Mehmood T, Terlizzi C, Esposito PMH, Franzese A, et al. Neutrophil extracellular traps as drivers of epithelial-mesenchymal transition in cancer cells. Front Immunol. 2025;16:1655019. https:\/\/doi.org\/10.3389\/fimmu.2025.1655019.","journal-title":"Front Immunol"},{"issue":"1","key":"516_CR86","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0339964","volume":"21","author":"K Urbonas","year":"2026","unstructured":"Urbonas K, Stachneviciute G, Jasukaitiene A, Ignatavicius P, Dambrauskas Z, Gulbinas A, et al. Overexpression of EMT-related transcription factors SNAI1 and ZEB1 is associated with more aggressive clinicopathological features of pancreatic cancer. PLoS ONE. 2026;21(1):e0339964. https:\/\/doi.org\/10.1371\/journal.pone.0339964.","journal-title":"PLoS ONE"},{"issue":"7","key":"516_CR87","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1002\/1878-0261.12084","volume":"11","author":"MK Jolly","year":"2017","unstructured":"Jolly MK, Tripathi SC, Somarelli JA, Hanash SM, Levine H. Epithelial\/mesenchymal plasticity: how have quantitative mathematical models helped improve our understanding? Mol Oncol. 2017;11(7):739\u201354. https:\/\/doi.org\/10.1002\/1878-0261.12084.","journal-title":"Mol Oncol"},{"issue":"10","key":"516_CR88","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1091\/mbc.E11-02-0103","volume":"22","author":"PA Gregory","year":"2011","unstructured":"Gregory PA, Bracken CP, Smith E, Bert AG, Wright JA, Roslan S, et al. An autocrine TGF-beta\/ZEB\/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition. Mol Biol Cell. 2011;22(10):1686\u201398. https:\/\/doi.org\/10.1091\/mbc.E11-02-0103.","journal-title":"Mol Biol Cell"},{"issue":"9","key":"516_CR89","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1038\/embor.2010.117","volume":"11","author":"S Brabletz","year":"2010","unstructured":"Brabletz S, Brabletz T. The ZEB\/miR-200 feedback loop\u2014a motor of cellular plasticity in development and cancer? EMBO Rep. 2010;11(9):670\u20137. https:\/\/doi.org\/10.1038\/embor.2010.117.","journal-title":"EMBO Rep"},{"issue":"11","key":"516_CR90","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1038\/s41416-021-01568-7","volume":"125","author":"S Garinet","year":"2021","unstructured":"Garinet S, Didelot A, Denize T, Perrier A, Beinse G, Leclere JB, et al. Clinical assessment of the miR-34, miR-200, ZEB1 and SNAIL EMT regulation hub underlines the differential prognostic value of EMT miRs to drive mesenchymal transition and prognosis in resected NSCLC. Br J Cancer. 2021;125(11):1544\u201351. https:\/\/doi.org\/10.1038\/s41416-021-01568-7.","journal-title":"Br J Cancer"},{"key":"516_CR91","doi-asserted-by":"publisher","unstructured":"Nie D, Fu J, Chen H, Cheng J, Fu J. Roles of MicroRNA-34a in Epithelial to Mesenchymal Transition, Competing Endogenous RNA Sponging and Its Therapeutic Potential. Int J Mol Sci. 2019;20(4). https:\/\/doi.org\/10.3390\/ijms20040861.","DOI":"10.3390\/ijms20040861"},{"issue":"10","key":"516_CR92","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1038\/s44321-025-00288-2","volume":"17","author":"AP Morel","year":"2025","unstructured":"Morel AP, Ouzounova M. Understanding cancer cell plasticity: EMT, respecialisation, and therapeutic opportunities. EMBO Mol Med. 2025;17(10):2531\u20132. https:\/\/doi.org\/10.1038\/s44321-025-00288-2.","journal-title":"EMBO Mol Med"},{"key":"516_CR93","doi-asserted-by":"publisher","DOI":"10.3390\/biology15030265","author":"E Peri","year":"2026","unstructured":"Peri E, Buttacavoli M, Roz E, Pucci-Minafra I, Feo S, Cancemi P. Decoding the molecular drivers of epithelial to mesenchymal transition in breast cancer: insights into epithelial plasticity and microenvironment crosstalk. Biology (Basel). 2026. https:\/\/doi.org\/10.3390\/biology15030265.","journal-title":"Biology (Basel)"},{"issue":"3","key":"516_CR94","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.3892\/ijmm.2017.3320","volume":"41","author":"H \u0160kovierov\u00e1","year":"2018","unstructured":"\u0160kovierov\u00e1 H, Okaj\u010dekov\u00e1 T, Strn\u00e1del J, Vidomanov\u00e1 E, Hala\u0161ov\u00e1 E. Molecular regulation of epithelial-to-mesenchymal transition in tumorigenesis (Review). Int J Mol Med. 2018;41(3):1187\u2013200. https:\/\/doi.org\/10.3892\/ijmm.2017.3320.","journal-title":"Int J Mol Med"},{"issue":"3","key":"516_CR95","doi-asserted-by":"publisher","first-page":"178","DOI":"10.4103\/ijd.IJD_387_18","volume":"65","author":"R Ahmadi-Beni","year":"2020","unstructured":"Ahmadi-Beni R, Vand-Rajabpour F, Ahmadifard M, Daneshpazhooh M, Noormohammadpour P, Rahmati J, et al. Decreased Sox2 Messenger RNA Expression in Basal Cell Carcinoma. Indian J Dermatol. 2020;65(3):178\u201382. https:\/\/doi.org\/10.4103\/ijd.IJD_387_18.","journal-title":"Indian J Dermatol"},{"issue":"2","key":"516_CR96","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s13402-023-00878-7","volume":"47","author":"MH Ahn","year":"2024","unstructured":"Ahn MH, Kim JH, Choi SJ, Kim HJ, Park DG, Oh KY, et al. Neuropilin-2 acts a critical determinant for epithelial-to-mesenchymal transition and aggressive behaviors of human head and neck cancer. Cell Oncol (Dordr). 2024;47(2):497\u2013511. https:\/\/doi.org\/10.1007\/s13402-023-00878-7.","journal-title":"Cell Oncol (Dordr)"},{"issue":"6","key":"516_CR97","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.13423","volume":"56","author":"D Li","year":"2023","unstructured":"Li D, Xia L, Huang P, Wang Z, Guo Q, Huang C, et al. Heterogeneity and plasticity of epithelial-mesenchymal transition (EMT) in cancer metastasis: focusing on partial EMT and regulatory mechanisms. Cell Prolif. 2023;56(6):e13423. https:\/\/doi.org\/10.1111\/cpr.13423.","journal-title":"Cell Prolif"},{"issue":"2","key":"516_CR98","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.gendis.2019.09.012","volume":"7","author":"Y Wang","year":"2020","unstructured":"Wang Y, Dong C, Zhou BP. Metabolic reprogram associated with epithelial-mesenchymal transition in tumor progression and metastasis. Genes Dis. 2020;7(2):172\u201384. https:\/\/doi.org\/10.1016\/j.gendis.2019.09.012.","journal-title":"Genes Dis"},{"key":"516_CR99","doi-asserted-by":"publisher","unstructured":"Thomson TM, Balcells C, Cascante M. Metabolic Plasticity and Epithelial-Mesenchymal Transition. J Clin Med. 2019;8(7). https:\/\/doi.org\/10.3390\/jcm8070967.","DOI":"10.3390\/jcm8070967"},{"issue":"3","key":"516_CR100","doi-asserted-by":"publisher","first-page":"252","DOI":"10.15252\/embj.201695204","volume":"36","author":"GL Semenza","year":"2017","unstructured":"Semenza GL. Hypoxia-inducible factors: coupling glucose metabolism and redox regulation with induction of the breast cancer stem cell phenotype. Embo j. 2017;36(3):252\u20139. https:\/\/doi.org\/10.15252\/embj.201695204.","journal-title":"Embo j"},{"issue":"1","key":"516_CR101","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41392-023-01332-8","volume":"8","author":"Z Chen","year":"2023","unstructured":"Chen Z, Han F, Du Y, Shi H, Zhou W. Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. Signal Transduct Target Ther. 2023;8(1):70. https:\/\/doi.org\/10.1038\/s41392-023-01332-8.","journal-title":"Signal Transduct Target Ther"},{"key":"516_CR102","doi-asserted-by":"publisher","unstructured":"Zaarour RF, Ribeiro M, Azzarone B, Kapoor S, Chouaib S. Tumor microenvironment-induced tumor cell plasticity: relationship with hypoxic stress and impact on tumor resistance. Front Oncol. 2023;13. https:\/\/doi.org\/10.3389\/fonc.2023.1222575.","DOI":"10.3389\/fonc.2023.1222575"},{"key":"516_CR103","doi-asserted-by":"publisher","unstructured":"Yushkov B, Chereshnev V, Korneva E, Yushkova V, Sarapultsev A. Stem-Cell Niches in Health and Disease: Microenvironmental Determinants of Regeneration and Pathology. Cells. 2025;14(13). https:\/\/doi.org\/10.3390\/cells14130981.","DOI":"10.3390\/cells14130981"},{"key":"516_CR104","doi-asserted-by":"publisher","unstructured":"Shang T, Jia Z, Li J, Cao H, Xu H, Cong L, et al. Unraveling the triad of hypoxia, cancer cell stemness, and drug resistance. J Hematol Oncol. 2025;18(1). https:\/\/doi.org\/10.1186\/s13045-025-01684-4.","DOI":"10.1186\/s13045-025-01684-4"},{"key":"516_CR105","doi-asserted-by":"publisher","first-page":"1809429","DOI":"10.3389\/fcell.2026.1809429","volume":"14","author":"Y Yuan","year":"2026","unstructured":"Yuan Y, Zhang D, Wang J, Jiang X, Duan L. Functions and mechanisms of circular RNAs in cancer stem cells and therapy resistance. Front Cell Dev Biol. 2026;14:1809429. https:\/\/doi.org\/10.3389\/fcell.2026.1809429.","journal-title":"Front Cell Dev Biol"},{"issue":"8113","key":"516_CR106","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/s41586-026-10157-8","volume":"653","author":"G Skrupskelyte","year":"2026","unstructured":"Skrupskelyte G, Rojo Arias JE, Ajith H, Dang Y, Rossetti D, Han S, et al. Precancerous niche remodelling dictates nascent tumour persistence. Nature. 2026;653(8113):242\u201353. https:\/\/doi.org\/10.1038\/s41586-026-10157-8.","journal-title":"Nature"},{"key":"516_CR107","doi-asserted-by":"publisher","unstructured":"Masoudi M, Moti D, Masoudi R, Auwal A, Hossain MM, Pronoy TUH, et al. Metabolic adaptations in cancer stem cells: A key to therapy resistance. Biochimica et Biophysica Acta (BBA) - Molecular Basis Disease. 2024;1870(5):167164. https:\/\/doi.org\/10.1016\/j.bbadis.2024.167164.","DOI":"10.1016\/j.bbadis.2024.167164"},{"issue":"8","key":"516_CR108","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1007\/s12015-025-10956-y","volume":"21","author":"LQ Keoh","year":"2025","unstructured":"Keoh LQ, Chiu CF, Ramasamy TS. Metabolic Plasticity and Cancer Stem Cell Metabolism: Exploring the Glycolysis-OXPHOS Switch as a Mechanism for Resistance and Tumorigenesis. Stem Cell Rev Rep. 2025;21(8):2446\u201368. https:\/\/doi.org\/10.1007\/s12015-025-10956-y.","journal-title":"Stem Cell Rev Rep"},{"key":"516_CR109","doi-asserted-by":"publisher","DOI":"10.3390\/cells14100717","author":"M Milella","year":"2025","unstructured":"Milella M, Rutigliano M, Pandolfo SD, Aveta A, Crocetto F, Ferro M, et al. The metabolic landscape of cancer stem cells: insights and implications for therapy. Cells. 2025. https:\/\/doi.org\/10.3390\/cells14100717.","journal-title":"Cells"},{"key":"516_CR110","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2026.1741800","author":"C Psvv","year":"2026","unstructured":"Psvv C, Sunil S, Thuyyath N, Kokkanti RR, Lavudi K. Mitochondrial metabolism in cancer stem cells (CSCs): molecular and diagnostic implications. Front Mol Biosci. 2026. https:\/\/doi.org\/10.3389\/fmolb.2026.1741800.","journal-title":"Front Mol Biosci"},{"issue":"2","key":"516_CR111","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16020237","volume":"16","author":"Y Miao","year":"2024","unstructured":"Miao Y, Wang P, Huang J, Qi X, Liang Y, Zhao W, et al. Metabolomics, transcriptome and single-cell RNA sequencing analysis of the metabolic heterogeneity between oral cancer stem cells and differentiated cancer cells. Cancers. 2024;16(2):237. https:\/\/doi.org\/10.3390\/cancers16020237.","journal-title":"Cancers"},{"issue":"7","key":"516_CR112","doi-asserted-by":"publisher","DOI":"10.3390\/antiox14070833","volume":"14","author":"M Bonanomi","year":"2025","unstructured":"Bonanomi M, Mallia S, Scalise M, Aramini T, Baldassari F, Brivio E, et al. Serine-driven metabolic plasticity drives adaptive resilience in pancreatic cancer cells. Antioxidants. 2025;14(7):833. https:\/\/doi.org\/10.3390\/antiox14070833.","journal-title":"Antioxidants"},{"key":"516_CR113","doi-asserted-by":"publisher","unstructured":"Tan J, Tang L, Zhang Q. The metabolic landscape of ovarian cancer stem cells: how do they survive? Front Oncol. 2026;15. https:\/\/doi.org\/10.3389\/fonc.2025.1738742.","DOI":"10.3389\/fonc.2025.1738742"},{"key":"516_CR114","doi-asserted-by":"publisher","unstructured":"Du M, Zhang J, Wicha MS, Luo M. Redox regulation of cancer stem cells: Biology and therapeutic implications. MedComm \u2013 Oncol. 2024;3(4). https:\/\/doi.org\/10.1002\/mog2.70005.","DOI":"10.1002\/mog2.70005"},{"issue":"8","key":"516_CR115","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41573-024-00979-4","volume":"23","author":"C Glorieux","year":"2024","unstructured":"Glorieux C, Liu S, Trachootham D, Huang P. Targeting ROS in cancer: rationale and strategies. Nat Rev Drug Discovery. 2024;23(8):583\u2013606. https:\/\/doi.org\/10.1038\/s41573-024-00979-4.","journal-title":"Nat Rev Drug Discovery"},{"key":"516_CR116","doi-asserted-by":"publisher","unstructured":"Wang B, Wang W, Xu Y, Liu R, Li R, Yang P, et al. Manipulating Redox Homeostasis of Cancer Stem Cells Overcome Chemotherapeutic Resistance through Photoactivatable Biomimetic Nanodiscs. Small. 2024;20(28). https:\/\/doi.org\/10.1002\/smll.202308539.","DOI":"10.1002\/smll.202308539"},{"issue":"4","key":"516_CR117","doi-asserted-by":"publisher","first-page":"425","DOI":"10.2174\/0115734099299174240522115944","volume":"21","author":"S Wang","year":"2025","unstructured":"Wang S, Han J, Wang Z, Liu X, Wang C, Nisar MF, et al. Targeted therapy of tumors and cancer stem cells based on oxidant-regulated redox pathway and its mechanism. Curr Comput Aided Drug Des. 2025;21(4):425\u201340. https:\/\/doi.org\/10.2174\/0115734099299174240522115944.","journal-title":"Curr Comput Aided Drug Des"},{"key":"516_CR118","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02413-8","author":"J Yang","year":"2025","unstructured":"Yang J, Wu Y, Lv X, Liu S, Yuan Z, Chen Y, et al. Neurotransmitters: an emerging target for therapeutic resistance to tumor immune checkpoint inhibitors. Mol Cancer. 2025. https:\/\/doi.org\/10.1186\/s12943-025-02413-8.","journal-title":"Mol Cancer"},{"issue":"1","key":"516_CR119","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13578-023-01073-9","volume":"13","author":"B Wang","year":"2023","unstructured":"Wang B, Han Y, Zhang Y, Zhao Q, Wang H, Wei J, et al. Overcoming acquired resistance to cancer immune checkpoint therapy: potential strategies based on molecular mechanisms. Cell Biosci. 2023;13(1):120. https:\/\/doi.org\/10.1186\/s13578-023-01073-9.","journal-title":"Cell Biosci"},{"key":"516_CR120","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.954992","volume":"13","author":"MT Bilotta","year":"2022","unstructured":"Bilotta MT, Antignani A, Fitzgerald DJ. Managing the TME to improve the efficacy of cancer therapy. Front Immunol. 2022;13:954992. https:\/\/doi.org\/10.3389\/fimmu.2022.954992.","journal-title":"Front Immunol"},{"key":"516_CR121","doi-asserted-by":"publisher","first-page":"1472772","DOI":"10.3389\/fimmu.2024.1472772","volume":"15","author":"L Wang","year":"2024","unstructured":"Wang L, Zhang L, Zhang Z, Wu P, Zhang Y, Chen X. Advances in targeting tumor microenvironment for immunotherapy. Front Immunol. 2024;15:1472772. https:\/\/doi.org\/10.3389\/fimmu.2024.1472772.","journal-title":"Front Immunol"},{"issue":"1","key":"516_CR122","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-021-01316-8","volume":"20","author":"L Xia","year":"2021","unstructured":"Xia L, Oyang L, Lin J, Tan S, Han Y, Wu N, et al. The cancer metabolic reprogramming and immune response. Mol Cancer. 2021;20(1):28. https:\/\/doi.org\/10.1186\/s12943-021-01316-8.","journal-title":"Mol Cancer"},{"issue":"6","key":"516_CR123","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","volume":"162","author":"CH Chang","year":"2015","unstructured":"Chang CH, Qiu J, O\u2019Sullivan D, Buck MD, Noguchi T, Curtis JD, et al. Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell. 2015;162(6):1229\u201341. https:\/\/doi.org\/10.1016\/j.cell.2015.08.016.","journal-title":"Cell"},{"issue":"2","key":"516_CR124","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/ijc.33781","volume":"150","author":"Y Li","year":"2022","unstructured":"Li Y, Tang J, Jiang J, Chen Z. Metabolic checkpoints and novel approaches for immunotherapy against cancer. Int J Cancer. 2022;150(2):195\u2013207. https:\/\/doi.org\/10.1002\/ijc.33781.","journal-title":"Int J Cancer"},{"issue":"1","key":"516_CR125","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41577-025-01208-8","volume":"26","author":"F Huber","year":"2026","unstructured":"Huber F, Bassani-Sternberg M. Defects in antigen processing and presentation: mechanisms, immune evasion and implications for cancer vaccine development. Nat Rev Immunol. 2026;26(1):23\u201334. https:\/\/doi.org\/10.1038\/s41577-025-01208-8.","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"516_CR126","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41568-021-00339-z","volume":"21","author":"S Jhunjhunwala","year":"2021","unstructured":"Jhunjhunwala S, Hammer C, Delamarre L. Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion. Nat Rev Cancer. 2021;21(5):298\u2013312. https:\/\/doi.org\/10.1038\/s41568-021-00339-z.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"516_CR127","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12943-025-02265-2","volume":"24","author":"Y Pan","year":"2025","unstructured":"Pan Y, Yuan C, Zeng C, Sun C, Xia L, Wang G, et al. Cancer stem cells and niches: challenges in immunotherapy resistance. Mol Cancer. 2025;24(1):52. https:\/\/doi.org\/10.1186\/s12943-025-02265-2.","journal-title":"Mol Cancer"},{"key":"516_CR128","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1620807","author":"G Yu","year":"2025","unstructured":"Yu G, Gong J. Targeting CSC-immune cell crosstalk to overcome chemoresistance and enhance immunotherapy efficacy. Front Immunol. 2025. https:\/\/doi.org\/10.3389\/fimmu.2025.1620807.","journal-title":"Front Immunol"},{"issue":"1","key":"516_CR129","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ccell.2025.11.001","volume":"44","author":"W Guo","year":"2026","unstructured":"Guo W, Luan J, Huang X, Leon D, Gang S, Nicholson B, et al. Tumor-initiating stem cells fine-tune the plasticity of neutrophils to sculpt a protective niche. Cancer Cell. 2026;44(1):94\u201311100000000000. https:\/\/doi.org\/10.1016\/j.ccell.2025.11.001.","journal-title":"Cancer Cell"},{"key":"516_CR130","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.937327","volume":"13","author":"B Huang","year":"2022","unstructured":"Huang B, Miao L, Liu J, Zhang J, Li Y. A promising antitumor method: targeting CSC with immune cells modified with CAR. Front Immunol. 2022;13:937327. https:\/\/doi.org\/10.3389\/fimmu.2022.937327.","journal-title":"Front Immunol"},{"key":"516_CR131","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1114621","volume":"13","author":"J An","year":"2023","unstructured":"An J, Hu X, Liu F. Current understanding of cancer stem cells: immune evasion and targeted immunotherapy in gastrointestinal malignancies. Front Oncol. 2023;13:1114621. https:\/\/doi.org\/10.3389\/fonc.2023.1114621.","journal-title":"Front Oncol"},{"key":"516_CR132","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1714954","volume":"16","author":"Y Duan","year":"2025","unstructured":"Duan Y, Li A, Miao D, Tan D, Wang K, Shi J. Colorectal cancer stem cells crosstalk in tumor immune microenvironment and targeted therapeutic strategies. Front Immunol. 2025;16:1714954. https:\/\/doi.org\/10.3389\/fimmu.2025.1714954.","journal-title":"Front Immunol"},{"issue":"6","key":"516_CR133","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1080\/14796694.2025.2461443","volume":"21","author":"A Jan","year":"2025","unstructured":"Jan A, Sofi S, Jan N, Mir MA. An update on cancer stem cell survival pathways involved in chemoresistance in triple-negative breast cancer. Future Oncol. 2025;21(6):715\u201335. https:\/\/doi.org\/10.1080\/14796694.2025.2461443.","journal-title":"Future Oncol"},{"issue":"1","key":"516_CR134","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/s43018-025-01067-1","volume":"7","author":"NL Silver","year":"2026","unstructured":"Silver NL, Dai J, Kerr TD, Altemus J, Garg R, Simmons H, et al. Intratumoral bacteria are immunosuppressive and promote immunotherapy resistance in head and neck squamous cell carcinoma. Nat Cancer. 2026;7(1):80\u201397. https:\/\/doi.org\/10.1038\/s43018-025-01067-1.","journal-title":"Nat Cancer"},{"issue":"4","key":"516_CR135","doi-asserted-by":"publisher","first-page":"445","DOI":"10.2174\/1574888x18666221017142032","volume":"18","author":"M Y\u0131lmaz","year":"2023","unstructured":"Y\u0131lmaz M, Kaplan F, Mender I, Gryaznov SM, Dikmen ZG. Cancer Stem Cells and Anti-tumor Immunity. Curr Stem Cell Res Ther. 2023;18(4):445\u201359. https:\/\/doi.org\/10.2174\/1574888x18666221017142032.","journal-title":"Curr Stem Cell Res Ther"},{"key":"516_CR136","doi-asserted-by":"publisher","DOI":"10.3390\/cells14070538","author":"L Haddadin","year":"2025","unstructured":"Haddadin L, Sun X. Stem cells in cancer: from mechanisms to therapeutic strategies. Cells. 2025. https:\/\/doi.org\/10.3390\/cells14070538.","journal-title":"Cells"},{"key":"516_CR137","doi-asserted-by":"publisher","unstructured":"Mathan SV, Singh RP. Cancer Stem Cells Connecting to Immunotherapy: Key Insights, Challenges, and Potential Treatment Opportunities. Cancers (Basel). 2025;17(13). https:\/\/doi.org\/10.3390\/cancers17132100.","DOI":"10.3390\/cancers17132100"},{"key":"516_CR138","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.3332\/ecancer.2025.2016","volume":"19","author":"I Barjij","year":"2025","unstructured":"Barjij I, Meliani M. Cancer stem cells and post-therapy tumour recurrence: a systematic review of mechanistic pathways and translational gaps. Ecancermedicalscience. 2025;19:2016. https:\/\/doi.org\/10.3332\/ecancer.2025.2016.","journal-title":"Ecancermedicalscience"},{"issue":"7","key":"516_CR139","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1053\/j.gastro.2015.07.064","volume":"149","author":"D Wang","year":"2015","unstructured":"Wang D, Fu L, Sun H, Guo L, DuBois RN. Prostaglandin E2 Promotes Colorectal Cancer Stem Cell Expansion and Metastasis in Mice. Gastroenterology. 2015;149(7):1884-95.e4. https:\/\/doi.org\/10.1053\/j.gastro.2015.07.064.","journal-title":"Gastroenterology"},{"issue":"1","key":"516_CR140","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12943-023-01877-w","volume":"22","author":"Z Zeng","year":"2023","unstructured":"Zeng Z, Fu M, Hu Y, Wei Y, Wei X, Luo M. Regulation and signaling pathways in cancer stem cells: implications for targeted therapy for cancer. Mol Cancer. 2023;22(1):172. https:\/\/doi.org\/10.1186\/s12943-023-01877-w.","journal-title":"Mol Cancer"},{"issue":"1","key":"516_CR141","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.tips.2023.11.006","volume":"45","author":"Y Liu","year":"2024","unstructured":"Liu Y, Wang H. Biomarkers and targeted therapy for cancer stem cells. Trends Pharmacol Sci. 2024;45(1):56\u201366. https:\/\/doi.org\/10.1016\/j.tips.2023.11.006.","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"516_CR142","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01867-y","volume":"22","author":"Y Mai","year":"2023","unstructured":"Mai Y, Su J, Yang C, Xia C, Fu L. The strategies to cure cancer patients by eradicating cancer stem-like cells. Mol Cancer. 2023;22(1):171. https:\/\/doi.org\/10.1186\/s12943-023-01867-y.","journal-title":"Mol Cancer"},{"issue":"18","key":"516_CR143","doi-asserted-by":"publisher","first-page":"18960","DOI":"10.1002\/cam4.6520","volume":"12","author":"A Izadpanah","year":"2023","unstructured":"Izadpanah A, Mohammadkhani N, Masoudnia M, Ghasemzad M, Saeedian A, Mehdizadeh H, et al. Update on immune-based therapy strategies targeting cancer stem cells. Cancer Med. 2023;12(18):18960\u201380. https:\/\/doi.org\/10.1002\/cam4.6520.","journal-title":"Cancer Med"},{"key":"516_CR144","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15051608","author":"AS K\u00f6seer","year":"2023","unstructured":"K\u00f6seer AS, Di Gaetano S, Arndt C, Bachmann M, Dubrovska A. Immunotargeting of cancer stem cells. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15051608.","journal-title":"Cancers (Basel)"},{"key":"516_CR145","doi-asserted-by":"publisher","DOI":"10.2174\/0109298673393449250818052754","author":"G Khan","year":"2025","unstructured":"Khan G, Hanbashi A, Mawkili W, Kamli F, Ali MS, Ahmad S, et al. Cancer Stem Cell-targeted Antibody-drug Conjugates for Cancer Immunotherapy. Curr Med Chem. 2025. https:\/\/doi.org\/10.2174\/0109298673393449250818052754.","journal-title":"Curr Med Chem"},{"key":"516_CR146","doi-asserted-by":"publisher","unstructured":"Al-Khreisat MJ, Abdulsahib WK, Jasim IK, Malathi H, Nayak PP, Anand DA, et al. Therapeutic targeting of cancer stem cell-specific surface glycans and glycoproteins. Discov Oncol. 2026;17(1). https:\/\/doi.org\/10.1007\/s12672-026-04586-0.","DOI":"10.1007\/s12672-026-04586-0"},{"key":"516_CR147","doi-asserted-by":"publisher","DOI":"10.2174\/1381612823666171115105252","author":"AF Cruz","year":"2017","unstructured":"Cruz AF, Fonseca NA, Moura V, Simoes S, Moreira JN. Targeting cancer stem cells and non-stem cancer cells: the potential of lipid-based nanoparticles. Curr Pharm Des. 2017. https:\/\/doi.org\/10.2174\/1381612823666171115105252.","journal-title":"Curr Pharm Des"},{"issue":"7","key":"516_CR148","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2018.1440169","volume":"7","author":"Y Wang","year":"2018","unstructured":"Wang Y, Chen M, Wu Z, Tong C, Dai H, Guo Y, et al. CD133-directed CAR T cells for advanced metastasis malignancies: a phase I trial. Oncoimmunology. 2018;7(7):e1440169. https:\/\/doi.org\/10.1080\/2162402x.2018.1440169.","journal-title":"Oncoimmunology"},{"issue":"11","key":"516_CR149","doi-asserted-by":"publisher","first-page":"5516","DOI":"10.1016\/j.ymthe.2025.08.014","volume":"33","author":"W Fang","year":"2025","unstructured":"Fang W, Lu Z, Ge J, Zhang S, Zheng R, Yin W, et al. Preclinical development and a phase 1 trial of IMC001, an EpCAM-targeted CAR-T cell therapy, in patients with advanced gastric cancer. Mol Ther. 2025;33(11):5516\u201329. https:\/\/doi.org\/10.1016\/j.ymthe.2025.08.014.","journal-title":"Mol Ther"},{"key":"516_CR150","doi-asserted-by":"publisher","unstructured":"Veschi V, Turdo A, Stassi G. Novel insights into cancer stem cells targeting: CAR-T therapy and epigenetic drugs as new pillars in cancer treatment. Front Mole Med. 2023;3. https:\/\/doi.org\/10.3389\/fmmed.2023.1120090.","DOI":"10.3389\/fmmed.2023.1120090"},{"issue":"4","key":"516_CR151","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.7150\/ijbs.101025","volume":"21","author":"F Zheng","year":"2025","unstructured":"Zheng F, Zhang S, Chang AE, Moon JJ, Wicha MS, Wang SX, et al. Breaking Immunosuppression to Enhance Cancer Stem Cell-Targeted Immunotherapy. Int J Biol Sci. 2025;21(4):1819\u201336. https:\/\/doi.org\/10.7150\/ijbs.101025.","journal-title":"Int J Biol Sci"},{"issue":"1","key":"516_CR152","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/s41392-025-02360-2","volume":"10","author":"H Lee","year":"2025","unstructured":"Lee H, Kim B, Park J, Park S, Yoo G, Yum S, et al. Cancer stem cells: landscape, challenges and emerging therapeutic innovations. Signal Transduct Target Ther. 2025;10(1):248. https:\/\/doi.org\/10.1038\/s41392-025-02360-2.","journal-title":"Signal Transduct Target Ther"},{"key":"516_CR153","doi-asserted-by":"publisher","unstructured":"Khan G, Hanbashi A, Mawkili W, Kamli F, Ali MS, Ahmad S, et al. Cancer Stem Cell-targeted Antibody-drug Conjugates for Cancer Immunotherapy. Curr Med Chem. 2025;32. https:\/\/doi.org\/10.2174\/0109298673393449250818052754.","DOI":"10.2174\/0109298673393449250818052754"},{"key":"516_CR154","doi-asserted-by":"publisher","unstructured":"Zhang Y, Wang X. Targeting the Wnt\/\u03b2-catenin signaling pathway in cancer. J Hematol Oncol. 2020;13(1). https:\/\/doi.org\/10.1186\/s13045-020-00990-3.","DOI":"10.1186\/s13045-020-00990-3"},{"issue":"1","key":"516_CR155","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s13045-020-00990-3","volume":"13","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Wang X. Targeting the Wnt\/\u03b2-catenin signaling pathway in cancer. J Hematol Oncol. 2020;13(1):165. https:\/\/doi.org\/10.1186\/s13045-020-00990-3.","journal-title":"J Hematol Oncol"},{"key":"516_CR156","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241310448","author":"R Kleszcz","year":"2023","unstructured":"Kleszcz R, Fr\u0105ckowiak M, Dorna D, Paluszczak J. Combinations of PRI-724 Wnt\/\u03b2-catenin pathway inhibitor with vismodegib, erlotinib, or HS-173 synergistically inhibit head and neck squamous cancer cells. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms241310448.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"516_CR157","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41392-022-00999-9","volume":"7","author":"M He","year":"2022","unstructured":"He M, Cao C, Ni Z, Liu Y, Song P, Hao S, et al. PROTACs: great opportunities for academia and industry (an update from 2020 to 2021). Signal Transduct Target Ther. 2022;7(1):181. https:\/\/doi.org\/10.1038\/s41392-022-00999-9.","journal-title":"Signal Transduct Target Ther"},{"issue":"7","key":"516_CR158","doi-asserted-by":"publisher","first-page":"398","DOI":"10.4252\/wjsc.v11.i7.398","volume":"11","author":"FY Du","year":"2019","unstructured":"Du FY, Zhou QF, Sun WJ, Chen GL. Targeting cancer stem cells in drug discovery: Current state and future perspectives. World J Stem Cells. 2019;11(7):398\u2013420. https:\/\/doi.org\/10.4252\/wjsc.v11.i7.398.","journal-title":"World J Stem Cells"},{"issue":"20","key":"516_CR159","doi-asserted-by":"publisher","first-page":"6021","DOI":"10.1158\/1078-0432.Ccr-19-0365","volume":"25","author":"KJ Norsworthy","year":"2019","unstructured":"Norsworthy KJ, By K, Subramaniam S, Zhuang L, Del Valle PL, Przepiorka D, et al. FDA Approval Summary: Glasdegib for Newly Diagnosed Acute Myeloid Leukemia. Clin Cancer Res. 2019;25(20):6021\u20135. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-19-0365.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"516_CR160","doi-asserted-by":"publisher","first-page":"182","DOI":"10.3892\/or.2022.8397","volume":"48","author":"Y Si","year":"2022","unstructured":"Si Y, Li L, Zhang W, Liu Q, Liu B. GANT61 exerts anticancer cell and anticancer stem cell capacity in colorectal cancer by blocking the Wnt\/\u03b2-catenin and Notch signalling pathways. Oncol Rep. 2022;48(4):182. https:\/\/doi.org\/10.3892\/or.2022.8397.","journal-title":"Oncol Rep"},{"key":"516_CR161","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.650772","volume":"9","author":"V Kumar","year":"2021","unstructured":"Kumar V, Vashishta M, Kong L, Wu X, Lu JJ, Guha C, et al. The Role of Notch, Hedgehog, and Wnt Signaling Pathways in the Resistance of Tumors to Anticancer Therapies. Front Cell Dev Biol. 2021;9:650772. https:\/\/doi.org\/10.3389\/fcell.2021.650772.","journal-title":"Front Cell Dev Biol"},{"issue":"9","key":"516_CR162","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.4252\/wjsc.v7.i9.1185","volume":"7","author":"DL Dragu","year":"2015","unstructured":"Dragu DL, Necula LG, Bleotu C, Diaconu CC, Chivu-Economescu M. Therapies targeting cancer stem cells: Current trends and future challenges. World J Stem Cells. 2015;7(9):1185\u2013201. https:\/\/doi.org\/10.4252\/wjsc.v7.i9.1185.","journal-title":"World J Stem Cells"},{"key":"516_CR163","doi-asserted-by":"publisher","unstructured":"Bhal S, Kundu CN. Targeting crosstalk of signaling pathways in cancer stem cells: a promising approach for development of novel anti-cancer therapeutics. Med Oncol. 2023;40(2). https:\/\/doi.org\/10.1007\/s12032-022-01905-7.","DOI":"10.1007\/s12032-022-01905-7"},{"issue":"4","key":"516_CR164","doi-asserted-by":"publisher","DOI":"10.1002\/mog2.62","volume":"2","author":"J Talukdar","year":"2023","unstructured":"Talukdar J, Srivastava TP, Sahoo OS, Karmakar A, Rai AK, Sarma A, et al. Cancer stem cells: signaling pathways and therapeutic targeting. MedComm Oncol. 2023;2(4):e62. https:\/\/doi.org\/10.1002\/mog2.62.","journal-title":"MedComm Oncol"},{"key":"516_CR165","doi-asserted-by":"publisher","unstructured":"Yang Y, Li X, Wang T, Guo Q, Xi T, Zheng L. Emerging agents that target signaling pathways in cancer stem cells. J Hematol Oncol. 2020;13(1). https:\/\/doi.org\/10.1186\/s13045-020-00901-6.","DOI":"10.1186\/s13045-020-00901-6"},{"key":"516_CR166","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1125174","author":"MC Borlongan","year":"2023","unstructured":"Borlongan MC, Wang H. Profiling and targeting cancer stem cell signaling pathways for cancer therapeutics. Front Cell Dev Biol. 2023. https:\/\/doi.org\/10.3389\/fcell.2023.1125174.","journal-title":"Front Cell Dev Biol"},{"key":"516_CR167","doi-asserted-by":"publisher","unstructured":"Yousefnia S, Seyed Forootan F, Seyed Forootan S, Nasr Esfahani MH, Gure AO, Ghaedi K. Mechanistic Pathways of Malignancy in Breast Cancer Stem Cells. Front Oncol. 2020;10. https:\/\/doi.org\/10.3389\/fonc.2020.00452.","DOI":"10.3389\/fonc.2020.00452"},{"key":"516_CR168","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.phrs.2019.02.027","volume":"142","author":"S Chatterjee","year":"2019","unstructured":"Chatterjee S, Sil PC. Targeting the crosstalks of Wnt pathway with hedgehog and notch for cancer therapy. Pharmacol Res. 2019;142:251\u201361. https:\/\/doi.org\/10.1016\/j.phrs.2019.02.027.","journal-title":"Pharmacol Res"},{"key":"516_CR169","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.canlet.2017.03.008","volume":"396","author":"Y Li","year":"2017","unstructured":"Li Y, Atkinson K, Zhang T. Combination of chemotherapy and cancer stem cell targeting agents: Preclinical and clinical studies. Cancer Lett. 2017;396:103\u20139. https:\/\/doi.org\/10.1016\/j.canlet.2017.03.008.","journal-title":"Cancer Lett"},{"issue":"13","key":"516_CR170","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241310448","volume":"24","author":"R Kleszcz","year":"2023","unstructured":"Kleszcz R, Fr\u0105ckowiak M, Dorna D, Paluszczak J. Combinations of PRI-724 Wnt\/\u03b2-catenin pathway inhibitor with vismodegib, erlotinib, or HS-173 synergistically inhibit head and neck squamous cancer cells. Int J Mol Sci. 2023;24(13):10448. https:\/\/doi.org\/10.3390\/ijms241310448.","journal-title":"Int J Mol Sci"},{"key":"516_CR171","doi-asserted-by":"publisher","DOI":"10.3390\/cells12162083","author":"P Cierpikowski","year":"2023","unstructured":"Cierpikowski P, Leszczyszyn A, Bar J. The role of hedgehog signaling pathway in head and neck squamous cell carcinoma. Cells. 2023. https:\/\/doi.org\/10.3390\/cells12162083.","journal-title":"Cells"},{"key":"516_CR172","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8070912","author":"MS Roca","year":"2019","unstructured":"Roca MS, Di Gennaro E, Budillon A. Implication for Cancer Stem Cells in Solid Cancer Chemo-Resistance: Promising Therapeutic Strategies Based on the Use of HDAC Inhibitors. J Clin Med. 2019. https:\/\/doi.org\/10.3390\/jcm8070912.","journal-title":"J Clin Med"},{"key":"516_CR173","doi-asserted-by":"publisher","unstructured":"Lu Z, Qiang Z, Lei W, Cai Z. Mechanisms of Resistance to Chemotherapy in Hypopharyngeal Carcinoma. Biomed. 2025;13(10). https:\/\/doi.org\/10.3390\/biomedicines13102485.","DOI":"10.3390\/biomedicines13102485"},{"key":"516_CR174","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.semcancer.2018.08.002","volume":"53","author":"Y Zhao","year":"2018","unstructured":"Zhao Y, Dong Q, Li J, Zhang K, Qin J, Zhao J, et al. Targeting cancer stem cells and their niche: perspectives for future therapeutic targets and strategies. Semin Cancer Biol. 2018;53:139\u201355. https:\/\/doi.org\/10.1016\/j.semcancer.2018.08.002.","journal-title":"Semin Cancer Biol"},{"key":"516_CR175","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2019.00016","author":"A Turdo","year":"2019","unstructured":"Turdo A, Veschi V, Gaggianesi M, Chinnici A, Bianca P, Todaro M, et al. Meeting the challenge of targeting cancer stem cells. Front Cell Dev Biol. 2019. https:\/\/doi.org\/10.3389\/fcell.2019.00016.","journal-title":"Front Cell Dev Biol"},{"key":"516_CR176","doi-asserted-by":"publisher","unstructured":"Mai Y, Su J, Yang C, Xia C, Fu L. The strategies to cure cancer patients by eradicating cancer stem-like cells. Mole Cancer. 2023;22(1). https:\/\/doi.org\/10.1186\/s12943-023-01867-y.","DOI":"10.1186\/s12943-023-01867-y"},{"key":"516_CR177","doi-asserted-by":"publisher","first-page":"9012369","DOI":"10.1155\/2016\/9012369","volume":"2016","author":"B Sainz Jr","year":"2016","unstructured":"Sainz B Jr, Carron E, Vallespin\u00f3s M, Machado HL. Cancer Stem Cells and Macrophages: Implications in Tumor Biology and Therapeutic Strategies. Mediators Inflamm. 2016;2016:9012369. https:\/\/doi.org\/10.1155\/2016\/9012369.","journal-title":"Mediators Inflamm"},{"issue":"1","key":"516_CR178","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s12672-026-04748-0","volume":"17","author":"TN AlRamadneh","year":"2026","unstructured":"AlRamadneh TN, Aditya FA, Abdulsahib WK, Jasim IK, Malathi H, Nayak PP, et al. Exosomes serve as natural nanocarriers targeting cancer stem cells to advance precision oncology. Discover Oncology. 2026;17(1):599. https:\/\/doi.org\/10.1007\/s12672-026-04748-0.","journal-title":"Discover Oncology"},{"key":"516_CR179","doi-asserted-by":"publisher","unstructured":"Vander Linden C, Corbet C. Therapeutic Targeting of Cancer Stem Cells: Integrating and Exploiting the Acidic Niche. Front Oncol. 2019;9. https:\/\/doi.org\/10.3389\/fonc.2019.00159.","DOI":"10.3389\/fonc.2019.00159"},{"issue":"7","key":"516_CR180","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1007\/s11427-024-2884-2","volume":"68","author":"Q Hao","year":"2025","unstructured":"Hao Q, Bai Y, Guan R, Dong R, Bai W, Hamdy H, et al. VPS35\/Retromer-dependent MT1-MMP regulation confers melanoma metastasis. Sci China Life Sci. 2025;68(7):1996\u20132009. https:\/\/doi.org\/10.1007\/s11427-024-2884-2.","journal-title":"Sci China Life Sci"},{"key":"516_CR181","doi-asserted-by":"publisher","first-page":"3714190","DOI":"10.1155\/2017\/3714190","volume":"2017","author":"EY Lau","year":"2017","unstructured":"Lau EY, Ho NP, Lee TK. Cancer Stem Cells and Their Microenvironment: Biology and Therapeutic Implications. Stem Cells Int. 2017;2017:3714190. https:\/\/doi.org\/10.1155\/2017\/3714190.","journal-title":"Stem Cells Int"},{"issue":"3","key":"516_CR182","doi-asserted-by":"publisher","first-page":"98","DOI":"10.62347\/gqzh3508","volume":"14","author":"W Zhou","year":"2025","unstructured":"Zhou W. Epigenetic crosstalk between stem cells and tumors: mechanisms and emerging perspectives. American Journal of Stem Cells. 2025;14(3):98\u2013133. https:\/\/doi.org\/10.62347\/gqzh3508.","journal-title":"American Journal of Stem Cells"},{"key":"516_CR183","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12102780","author":"A Tanabe","year":"2020","unstructured":"Tanabe A, Sahara H. The metabolic heterogeneity and flexibility of cancer stem cells. Cancers (Basel). 2020. https:\/\/doi.org\/10.3390\/cancers12102780.","journal-title":"Cancers (Basel)"},{"key":"516_CR184","doi-asserted-by":"publisher","unstructured":"Stouras I, Vasileiou M, Kanatas PF, Tziona E, Tsianava C, Theocharis S. Metabolic Profiles of Cancer Stem Cells and Normal Stem Cells and Their Therapeutic Significance. Cells. 2023;12(23). https:\/\/doi.org\/10.3390\/cells12232686.","DOI":"10.3390\/cells12232686"},{"key":"516_CR185","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16030624","author":"SM Tu","year":"2024","unstructured":"Tu SM, Chen JZ, Singh SR, Maraboyina S, Gokden N, Hsu PC, et al. Stem cell theory of cancer: clinical implications for cellular metabolism and anti-cancer metabolomics. Cancers (Basel). 2024. https:\/\/doi.org\/10.3390\/cancers16030624.","journal-title":"Cancers (Basel)"},{"key":"516_CR186","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.537930","volume":"10","author":"A Mukha","year":"2020","unstructured":"Mukha A, Dubrovska A. Metabolic Targeting of Cancer Stem Cells. Front Oncol. 2020;10:537930. https:\/\/doi.org\/10.3389\/fonc.2020.537930.","journal-title":"Front Oncol"},{"key":"516_CR187","doi-asserted-by":"publisher","first-page":"203","DOI":"10.3389\/fonc.2018.00203","volume":"8","author":"V Snyder","year":"2018","unstructured":"Snyder V, Reed-Newman TC, Arnold L, Thomas SM, Anant S. Cancer Stem Cell Metabolism and Potential Therapeutic Targets. Front Oncol. 2018;8:203. https:\/\/doi.org\/10.3389\/fonc.2018.00203.","journal-title":"Front Oncol"},{"issue":"1","key":"516_CR188","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.semradonc.2018.10.003","volume":"29","author":"M Luo","year":"2019","unstructured":"Luo M, Wicha MS. Targeting cancer stem cell redox metabolism to enhance therapy responses. Semin Radiat Oncol. 2019;29(1):42\u201354. https:\/\/doi.org\/10.1016\/j.semradonc.2018.10.003.","journal-title":"Semin Radiat Oncol"},{"key":"516_CR189","doi-asserted-by":"publisher","unstructured":"Wei Y, Zhang B, Bie Q, He B. Metabolic regulation in the senescence process of stem cells. Stem Cells Transl Med. 2025;14(9). https:\/\/doi.org\/10.1093\/stcltm\/szaf041.","DOI":"10.1093\/stcltm\/szaf041"},{"issue":"24","key":"516_CR190","doi-asserted-by":"publisher","first-page":"15279","DOI":"10.1021\/acs.jmedchem.0c01336","volume":"63","author":"PS Kharkar","year":"2020","unstructured":"Kharkar PS. Cancer Stem Cell (CSC) Inhibitors in Oncology\u2014A Promise for a Better Therapeutic Outcome: State of the Art and Future Perspectives. J Med Chem. 2020;63(24):15279\u2013307. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c01336.","journal-title":"J Med Chem"},{"issue":"1","key":"516_CR191","doi-asserted-by":"publisher","first-page":"155","DOI":"10.7150\/thno.103376","volume":"15","author":"M Jiang","year":"2025","unstructured":"Jiang M, Fang H, Tian H. Metabolism of cancer cells and immune cells in the initiation, progression, and metastasis of cancer. Theranostics. 2025;15(1):155\u201388. https:\/\/doi.org\/10.7150\/thno.103376.","journal-title":"Theranostics"},{"issue":"8","key":"516_CR192","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41571-023-00774-x","volume":"20","author":"X Deng","year":"2023","unstructured":"Deng X, Qing Y, Horne D, Huang H, Chen J. The roles and implications of RNA m(6)A modification in cancer. Nat Rev Clin Oncol. 2023;20(8):507\u201326. https:\/\/doi.org\/10.1038\/s41571-023-00774-x.","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Molecular Biomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-026-00516-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43556-026-00516-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-026-00516-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T07:17:19Z","timestamp":1784272639000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43556-026-00516-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":192,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["516"],"URL":"https:\/\/doi.org\/10.1186\/s43556-026-00516-2","relation":{},"ISSN":["2662-8651"],"issn-type":[{"value":"2662-8651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"assertion":[{"value":"7 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. This article is a review of previously published studies and does not contain any original studies with human participants or animals performed by the authors.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"114"}}